Transplant Infectious Disease Program
The Transplant Infectious Disease Program, part of the Massachusetts General Hospital Transplant Center, is a part of the life-long care provided to organ, bone marrow and stem cell transplant recipients and others with increased risk for infections.
About This Program Transplant patients take medicines after the transplantation to prevent the immune system from attacking their new organ. These medicines are essential for your health after transplantation. However, these medicines also reduce your body’s ability to defend itself against illness caused by infection from bacteria, viruses or fungi.
The Transplant Infectious Disease Program at Mass General provides:
- Consultation for infectious disease management and prevention in transplant recipients and donors
- Pre- and posttransplant vaccination and individually designed strategies for preventing infections
- Travel advice in advance of or following travel by our patients
The integrated, multidisciplinary approach in the Transplant Infectious Disease Program involves all aspects of clinical care, basic, clinical and translational research, and education devoted to patients with an increased risk for infections.
Each member of the infectious disease team is committed to ensuring the best possible care for each patient with a compromised immune system as a result of organ, bone marrow or stem cell transplants.
The staff members of the Transplant Infectious Disease Program are all members of the Infectious Disease Division of Massachusetts General Hospital.
Conditions and Diseases
The care team at the Transplant Center encourages all patients and family members to learn more about conditions and diseases related to transplantation. The links below provide more information about conditions and diseases that might be treated within this program.
Cystic fibrosis (CF) is an inherited chronic disease that affects the lungs and digestive system. CF causes the body to produce thick, sticky mucus that leads to progressive lung infection and difficulty gaining weight.
Type 1 diabetes may also be known by a variety of other names, including the following: insulin-dependent diabetes mellitus (IDDM), juvenile diabetes, brittle diabetes, or sugar diabetes.
Renal failure refers to temporary or permanent damage to the kidneys that results in loss of normal kidney function.
Heart failure, also called congestive heart failure, is a condition in which the heart cannot pump enough oxygenated blood to meet the needs of the body's other organs.
Hepatitis A is a highly contagious and sometimes serious liver disease caused by the hepatitis A virus.
Hepatitis B is a blood-borne microorganism transmitted by exposure to the hepatitis B virus through infectious body fluids.
Hepatitis C (once called non-A, non-B hepatitis) is a liver disease caused by a recently identified blood-borne virus.
Emphysema is a chronic lung condition in which alveoli, or air sacs, may be destroyed, narrowed, collapsed, stretched or over-inflated.
Sarcoidosis is a rare disease that results from inflammation.
Type 1 diabetes may also be known by a variety of other names, including the following: insulin-dependent diabetes mellitus (IDDM), juvenile diabetes, brittle diabetes, and sugar diabetes.
Support and Wellness
Mass General is dedicated to ensuring that people understand their health care choices and have the necessary information to make decisions affecting their health and well being. The related support and wellness information listed below can play a role in treatment options.
Read the Transplant Center's award-winning patient education guide, Transplantation: What Do I Need to Know?
The following related clinical trials and research studies are currently seeking participants at Massachusetts General Hospital. Search for clinical trials and studies in another area of interest.
Cystic Fibrosis: VX09-809-102: A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Lumacaftor Monotherapy, and Lumacaftor and Ivacaftor Combination Therapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation [Cohort 4]
The Transplant Center celebrated Donate Life Month by raising public awareness about the importance of organ donation and also extending thanks to the many organ donors and families who have given the generous gift of life to others.
Clinicians at the Transplant Center received a National Health Information Award for developing an outstanding patient education book and streamlining the patient evaluation process.
The Department of Health and Human Services awarded the Transplant Center a Medal of Honor for its outstanding achievements in organ donation, including a donation rate of 75 percent or more eligible donors.
Transplant Infectious Disease Program55 Fruit Street
Boston, MA 02114
Public Transportation Access: yes
Disabled Access: yes
Request an appointment for your patient with one of our world-class transplant specialists.
Our approach to patient care brings together a team of transplant specialists who create a personalized treatment plan for each patient.